ANC Prescription - 2.5 Months Pregnancy (≈10 Weeks / First Trimester)

1. REGISTRATION & BOOKING DETAILS

• Record date of last menstrual period (LMP); calculate expected date of delivery (EDD)
• Record age, obstetric history (gravida, para, abortions)
• Height, weight, BMI
• Blood pressure (baseline)
• Fundal height check
• Confirm intrauterine pregnancy via USG (dating scan ideally in first trimester)

2. INVESTIGATIONS TO ORDER

At Sub-Centre Level

At PHC/CHC/FRU Level

First Trimester Screening (if available)

• USG dating scan (crown-rump length at 8-13+6 weeks)
• NT scan (Nuchal Translucency) at 11-13+6 weeks
• Double marker / PAPP-A + free beta-hCG (Down syndrome screen)
• Thalassemia + sickle cell screen (in high-risk regions)
• Rubella IgG (if not immunized)
• HCV, TB (if indicated)

3. PRESCRIPTION / DRUG CHART

A. Iron + Folic Acid (IFA) - MANDATORY

Rx: Ferrous Sulphate 100 mg + Folic Acid 500 mcg tablet 1 tablet daily after meals (to reduce gastric side effects) To be continued for 180 days (6 months) throughout pregnancy

• WHO recommends 30-60 mg elemental iron + 400 mcg folic acid daily
• Government of India programme: 100 mg elemental iron + 500 mcg folic acid for 100 days
• High-risk (NTD history, epilepsy, twins): Folic acid 4-5 mg/day

Note: Folic acid is most critical in the first 12 weeks to prevent neural tube defects (NTDs). Ideally started pre-conception, but must be continued throughout the first trimester.

B. Calcium Supplementation

Rx: Calcium carbonate 500 mg + Vitamin D3 250 IU tablet 1-2 tablets daily (total 1000-1500 mg calcium/day)

• WHO recommends calcium supplementation (1.5-2 g/day) especially where dietary intake is low, to reduce risk of pre-eclampsia
• Calcium and iron should ideally be taken at separate times (calcium inhibits iron absorption)

C. Vitamin D

Rx: Vitamin D3 400-600 IU/day (as part of prenatal multivitamin or standalone)

• Deficiency linked to preeclampsia, GDM, preterm birth

D. Multivitamin / Prenatal Supplement

Rx: Prenatal multivitamin (containing folate, zinc, iodine, B12, B6) 1 tablet daily

• Zinc: 11 mg/day
• Iodine: 150 mcg/day (critical for fetal brain development)
• B12: important for vegetarians/vegans (2.6 mcg/day)
• B6 (pyridoxine 10-25 mg): may help with nausea/vomiting of pregnancy

E. Medication for Nausea (if needed - very common at 10 weeks)

Rx: Doxylamine 10 mg + Pyridoxine (B6) 10 mg 1-2 tablets at night (titrate up as needed)

Rx: Metoclopramide 10 mg TDS (for moderate nausea/vomiting) OR Ondansetron 4 mg BD (for severe vomiting - use with caution in first trimester)

F. Aspirin (for Pre-eclampsia Prevention - if risk factors present)

Rx: Aspirin 75-150 mg at bedtime Start before 16 weeks (ideally 12 weeks) and continue to 36 weeks

• First pregnancy / nulliparous
• Previous pre-eclampsia
• Twin pregnancy
• Obesity (BMI >35)
• Diabetes
• Chronic hypertension
• Renal disease
• Age >40

G. Omega-3 Fatty Acids (optional, if available)

Rx: DHA 200-300 mg/day Supports fetal brain and eye development

4. IMMUNIZATION

Tetanus Toxoid (TT) / Td Vaccine

• If never immunized: Give Td-1 at first ANC visit (10 weeks is appropriate)
• Td-2: at least 4 weeks after Td-1 (but 2+ weeks before delivery)
• If previously immunized with 2+ doses and booster within 3 years: a single booster may suffice

Minimum interval between two doses: 1 month

5. COUNSELING POINTS (First Visit)

6. FOLLOW-UP SCHEDULE

Summary Prescription Card

Sources: Park's Textbook of Preventive and Social Medicine (ANC chapter); WHO Recommendations on Antenatal Care 2016 (updated 2024); ACOG/StatPearls Initial Antepartum Care guidelines; FOGSI Routine ANC Guidelines 2024; WHO Daily Iron and Folic Acid Supplementation in Pregnancy (updated July 2024)

Disclaimer: This is a general ANC framework. Individual clinical decisions should be made by a qualified healthcare provider based on the patient's full history, examination findings, and local protocols.

When to Start Iron and Calcium in Pregnancy

IRON (IFA Tablets)

Start: As early as possible - from the 1st ANC visit (ideally by 12 weeks)

• Iron deficiency in the first trimester is directly linked to preterm birth and low birth weight
• Fetal iron demand increases sharply in the second and third trimesters - stores must be built before that
• Anaemia in early pregnancy worsens the risk of postpartum haemorrhage and puerperal sepsis

CALCIUM

Start: After the first trimester - from 14 weeks (second trimester onward)

• Calcium demand increases most dramatically in the 2nd and 3rd trimesters as fetal skeletal mineralisation accelerates
• Daily intake of ≥1g/day calcium after the first trimester reduces pre-eclampsia risk by at least 50% and reduces preterm birth risk by 24% (Cochrane systematic review, 2014)
• Giving it from 14 weeks ensures adequate coverage through the critical growth period

KEY RULE: Never Take Iron and Calcium Together

Calcium inhibits iron absorption. The two tablets MUST be taken at separate times - at least 2-4 hours apart.

Recommended Timing Schedule

• Take with Vitamin C (orange juice, lemon water) - enhances absorption
• Avoid with tea, coffee, milk, or antacids - all reduce iron absorption

Quick Summary Table

Sources: India NHM National Guidelines for Calcium Supplementation During Pregnancy and Lactation; WHO Recommendations on ANC 2016 (updated 2024); WHO Calcium Supplementation Guideline; ACOG/CDC Prenatal Care Guidelines; Park's Textbook of Preventive & Social Medicine (ANC Chapter); Columbia University OBGYN Prenatal Care Protocol

Treatment for Hot Flushes (Vasomotor Symptoms)

Understanding the Mechanism

STEP 1 - LIFESTYLE MODIFICATIONS (All Women)

STEP 2 - HORMONAL THERAPY (Most Effective)

Primary indication: Moderate-to-severe hot flushes affecting quality of life

Estrogen Preparations

Important Rules for Hormone Therapy

• Women with intact uterus: Must add a progestogen to estrogen to prevent endometrial hyperplasia/cancer
• Oral: Medroxyprogesterone acetate (MPA), Micronized progesterone (preferred - safer)
• Intrauterine: Levonorgestrel IUS (Mirena) - delivers progestogen locally
• Women post-hysterectomy: Estrogen alone is safe (no progestogen needed)
• Lowest effective dose for shortest necessary duration - individualize
• Transdermal route is preferred in women at higher VTE/stroke risk

Contraindications to HRT

• History of breast cancer or estrogen-receptor positive cancer
• History of endometrial cancer (relative)
• Active or recent VTE / thrombophilia
• Undiagnosed vaginal bleeding
• Active liver disease
• Recent MI or stroke (within 6 months)

STEP 3 - NON-HORMONAL PHARMACOTHERAPY

A. Neurokinin Receptor Antagonists (Newest Class - Non-hormonal)

• Both work by blocking neurokinin B signalling on KNDy neurons - reducing hypothalamic thermoregulatory dysregulation without hormones
• Elinzanetant is the first dual NK1/NK3 antagonist - also improves sleep and quality of life
• Can be used first-line for moderate-to-severe hot flushes
• Fezolinetant caution: FDA added a boxed warning (Dec 2024) for rare but serious liver injury - monitor LFTs
• Elinzanetant advantage: No liver toxicity reported in Phase III OASIS trials

B. Antidepressants (SSRIs / SNRIs)

Note: Paroxetine is contraindicated in women on tamoxifen for breast cancer - it inhibits CYP2D6 and reduces tamoxifen effectiveness. Use venlafaxine instead in that setting.

C. Gabapentinoids

• Particularly useful if sleep disturbance and hot flushes co-exist
• Side effects: dizziness, drowsiness, weight gain

D. Clonidine

• Effect is modest; side effects (dry mouth, dizziness, constipation) often limit use
• Some current guidelines (e.g. Australasian Menopause Society) no longer recommend clonidine routinely

E. Oxybutynin

• Anticholinergic; shown to reduce hot flush frequency in some trials
• Dose: 2.5-5 mg/day
• Side effects: dry mouth, constipation, cognitive effects

STEP 4 - COMPLEMENTARY / ALTERNATIVE THERAPIES

Non-prescription remedies generally show minimal benefit. Large placebo effect in VMS trials (~30-40%) must be accounted for.

Quick Decision Guide

Hot Flushes
    │
    ├── Mild → Lifestyle modifications
    │
    ├── Moderate-Severe + No contraindications to HRT
    │       → MHT (Estrogen ± Progestogen) - GOLD STANDARD
    │
    ├── Moderate-Severe + Contraindications / Declines HRT
    │       → First choice: Fezolinetant OR Elinzanetant (NK antagonists)
    │         OR SSRIs/SNRIs (Venlafaxine, Paroxetine, Escitalopram)
    │         OR Gabapentin (especially with sleep disturbance)
    │
    └── On Tamoxifen for breast cancer
            → Venlafaxine or Gabapentin (avoid paroxetine)

Contraindications Summary

Sources: Lippincott Illustrated Reviews Pharmacology (Estrogen Therapy); Kaplan & Sadock's Comprehensive Textbook of Psychiatry (Alternatives to HRT); Swanson's Family Medicine Review; FDA approvals for Veozah (May 2023) and Lynkuet (October 2025); NAMS 2022 Hormone Therapy Position Statement; NAMS 2023 Nonhormone Therapy Position Statement; Cleveland Clinic Journal of Medicine 2024 (Non-hormone VMS therapies); Mayo Clinic 2024

Glykind M - Complete Drug Profile

Brand Identity

Composition

Note: There are 3 variants of Glykind M available - the standard is Gliclazide 80 mg + Metformin 500 mg per tablet.

Indication

• NOT for Type 1 diabetes
• NOT for diabetic ketoacidosis (DKA)

Mechanism of Action (How It Works)

Gliclazide (Sulfonylurea)

• Binds to ATP-sensitive K⁺ channels (K-ATP channels) on pancreatic beta cells
• Causes membrane depolarization → calcium influx → insulin release
• Stimulates insulin secretion from the pancreas regardless of blood glucose level
• Also has antioxidant properties and reduces platelet aggregation (unique among sulfonylureas)
• Effect: Lowers blood glucose by increasing insulin secretion

Metformin (Biguanide)

• Activates AMPK (AMP-activated protein kinase) in the liver
• Reduces hepatic glucose production (gluconeogenesis and glycogenolysis)
• Improves peripheral insulin sensitivity in muscle
• Reduces intestinal glucose absorption
• Does NOT cause hypoglycemia when used alone (insulin-independent action)
• Effect: Lowers blood glucose without stimulating insulin secretion

Combined Benefit

Dosage

Side Effects

Common

• Hypoglycemia (low blood sugar) - most important - sweating, tremors, dizziness, hunger, palpitations
• Nausea, vomiting
• Diarrhea, flatulence, constipation
• Altered taste / metallic taste (metformin)
• Stomach pain
• Headache, dizziness
• Upper respiratory tract infections

Serious (Rare)

Contraindications

Important Drug Interactions

Monitoring

Patient Counseling Points

1. Take with food - never skip a meal after taking this tablet
2. Carry glucose (sugar, juice, glucose tablets) at all times for hypoglycemia emergency
3. Avoid alcohol - increases both hypoglycemia and lactic acidosis risk
4. Inform doctor before any surgery, CT scan with contrast, or procedure
5. Do not skip doses - take at a fixed time daily
6. Diet + exercise remain essential parts of diabetes management
7. Report immediately: Unusual muscle pain, difficulty breathing, nausea/vomiting (possible lactic acidosis)
8. Report immediately: Sweating, shakiness, confusion (hypoglycemia)

Available Variants (Glykind M range - Mankind)

Sources: 1mg Drug Database (Glykind M, updated April 2026); PharmEasy Drug Profile; Netmeds; Mankind Pharma product information; Katzung's Basic and Clinical Pharmacology 16th Ed. (Oral antidiabetics section)

Is Gliclazide Good for Diabetes?

What Gliclazide Is

Evidence That Gliclazide Is Effective

1. Significant HbA1c Reduction

• Sulfonylureas as a class reduce HbA1c by ~1-2% (11-22 mmol/mol) from baseline
• In head-to-head studies, gliclazide reduced HbA1c by 2.44% vs 1.91% for glimepiride - showing superior glycemic control
• In meta-analysis of 19 RCTs (3083 patients), gliclazide was at least equally effective and slightly more effective than other oral antidiabetic drugs

2. Lowers Fasting Blood Glucose

• Reduces fasting glucose by 2-4 mmol/L - clinically meaningful

3. The ADVANCE Trial (Landmark Study)

• The ADVANCE trial - a large RCT of 11,140 patients - used gliclazide MR as the cornerstone of intensive glucose control
• Intensive control with gliclazide MR achieved HbA1c of 6.5% and significantly reduced nephropathy (kidney complications) by 21%
• This study confirmed gliclazide MR's long-term safety and cardiovascular neutrality

Why Gliclazide Is Considered BETTER Than Other Sulfonylureas

1. Lower Hypoglycemia Risk

• Gliclazide has a shorter half-life and reversible binding to beta-cell receptors
• This means insulin secretion is more glucose-dependent and less sustained
• Gliclazide MR has the lowest hypoglycemia risk among all sulfonylureas
• Vs older SUs (glibenclamide/glyburide): much safer, especially in elderly

2. Cardiovascular Safety - Selective Receptor Binding

• Binds selectively to SUR1 receptors on pancreatic beta cells
• Has minimal binding to cardiac SUR2A and vascular SUR2B receptors
• This means it does NOT impair ischemic preconditioning of the heart (protective mechanism during cardiac ischemia)
• Other older sulfonylureas (glibenclamide) block cardiac K-ATP channels and may worsen cardiac outcomes
• Gliclazide is considered cardiovascular safe / neutral

3. Antioxidant Properties (Unique Advantage)

• Gliclazide has a unique azabicyclo-octyl ring in its molecular structure
• This gives it free radical scavenging / antioxidant activity
• May protect pancreatic beta cells from oxidative stress-induced apoptosis
• May help preserve residual beta-cell function over time - slowing diabetes progression

4. Renal Safety - Usable in CKD

• Gliclazide is predominantly metabolized by the liver
• Its metabolites are inactive (no active metabolites)
• Can be used more safely in mild-to-moderate chronic kidney disease (CKD stage 1-3)
• Unlike glibenclamide, which has active metabolites that accumulate in renal failure causing dangerous prolonged hypoglycemia

5. Minimal Weight Gain

• All sulfonylureas cause some weight gain (1-4 kg) due to increased insulin
• The ADVANCE trial showed minimal weight gain with gliclazide MR over 5 years
• Better weight profile than glibenclamide

6. Beta-Cell Preservation

• Animal and in vitro studies suggest gliclazide may protect beta cells from apoptosis
• May offer potential benefit in early T2DM to preserve insulin secretory capacity

Gliclazide vs Other Diabetes Drugs - Where It Stands

When Gliclazide Is Particularly Useful

• When metformin alone is insufficient to control blood sugar
• As a second-line add-on to metformin
• When cost is a concern (very affordable)
• In resource-limited settings - widely available
• In mild-moderate CKD where SGLT-2i/GLP-1 may be contraindicated or unaffordable
• In elderly patients (using gliclazide MR - lower hypoglycemia risk)
• When rapid HbA1c reduction is needed

Limitations / When Gliclazide May Not Be the Best Choice

Current Guideline Position

Bottom Line

Gliclazide is a good, effective, and affordable drug for Type 2 diabetes. Among sulfonylureas, it is one of the safest and most preferred - with lower hypoglycemia risk, cardiovascular neutrality, antioxidant properties, and renal safety. It remains a cornerstone of T2DM management, especially in combination with metformin, in settings where newer expensive drugs (GLP-1, SGLT-2i) are not accessible or not indicated. Gliclazide MR once-daily is the preferred formulation.

Sources: Bansal et al., Indian Journal of Endocrinology and Metabolism (Systematic Review, 2025, PMID 40688616); Sahin et al., Diabetes Therapy (Scoping Review, 2024, PMID 38935188); ADVANCE Trial (NEJM, 2008); DiabetesontheNet Prescribing Pearls - Sulfonylureas; Gavin Publishers Review - Gliclazide as Preferred Modern Sulfonylurea; PMC Scoping Review on Gliclazide Position in T2DM Paradigm (PMC11263312)